Europe

Further Enhancing the Implementation of Quality Standards in Drug Demand Reduction Across Europe

The EU Strategy 2021-2025 puts further emphasis on QS and evidence-based interventions. Yet, the extent and ways in which QS are implemented in daily practices of drug prevention, treatment and harm reduction in the EU varies substantially. Some countries have successfully implemented QS. The general objective of this project is to enhance the implementation of QS in drug prevention, treatment and harm reduction throughout the EU, with more services, organizations and countries applying QS in

Synthetic cannabinoids in Europe – a review

Published by
EMCDDA
Publication Date

This report provides a technical review of the current body of knowledge regarding synthetic cannabinoids that are monitored by the the EU Early Warning System.

The aim of this report is to strengthen situational awareness of synthetic cannabinoids in Europe and to help stakeholders prepare for, and respond to, public health and social threats caused by such substances.

Increase access to hepatitis C (HCV) testing and care in drug services- a toolkit

Created by
EMCDDA

People who inject drugs (PWID) are a key population for the elimination of hepatitis C in Europe, and increasing their access to HCV testing and care is a goal in European and national hepatitis C policies. Despite this, HCV testing remains low among people who inject drugs and effective approaches to promote testing as the first element of a cascade of care are particularly needed.

Save the dates: Horizon Europe info-days take place between 28 June and 9 July 2021

The European Commission announces today the first edition of the Horizon Europe info-days, to take place online from 28 June to 9 July 2021. Horizon Europe is the EU’s key funding programme for research and innovation with a budget of €95.5 billion. The 10-day event will give the opportunity to prospective applicants, and other stakeholders of EU research and innovation, to receive information and ask questions about the novelties, main funding instruments and processes of